Possible Explanations for Why Voyager Therapeutics, Inc. (VYGR) Trades Today Down -6.27%

An interesting stock that came up in some of our conversations today is Voyager Therapeutics, Inc. (NASDAQ:VYGR). At current price of $12.85, the shares have already lost -0.86 points (-6.27% lower) from its previous close of $13.71. Should you buy or avoid them? The stock sets an active trading volume day with a reported 111309 contracts so far this session. VYGR shares had a relatively better volume day versus average trading capacity of 379.13 thousand shares, but with a 31.59 million float and a 0.66% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for VYGR stock indicates that the average analyst price target is $28.46 per share. This means the stock has a potential increase of 121.48% from where the VYGR share price has been trading recently.

During the recent trading session for Voyager Therapeutics, Inc. (NASDAQ:VYGR), the company witnessed their stock drop by $-0.15 over a week and tumble down $-1.85 from the price 20 days ago. When compared to their established 52-week high of $28.79, the high they recorded in their recent session happens to be higher. Their established 52-week high was attained by the company on 06/20/19. The recent low of $10.5 stood for a -55.37% since 02/15/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 2.59 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.

Looking at the current readings for Voyager Therapeutics, Inc., the two-week RSI stands at 48.85. This figure suggests that VYGR stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current VYGR readings is similarly very revealing as it has a stochastic reading of 81.38% at this stage. This figure means that VYGR share price today is being oversold.

Technical chart claims that Voyager Therapeutics, Inc. (VYGR) would settle between $13.88/share to $14.05/share level. However, if the stock price goes below the $13.43 mark, then the market for Voyager Therapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $13.15 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.29. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.

Analysts at Oppenheimer, assumed coverage of VYGR assigning Outperform rating, according to their opinion released on February 06. Raymond James analysts bumped their rating on Voyager Therapeutics, Inc. (NASDAQ:VYGR) stock from Outperform to Strong Buy in a separate flash note issued to investors on November 15. Analysts at BTIG Research, made their first call for the equity with a Buy recommendation, according to a research note that dated back to September 10.

VYGR equity has an average rating of 1.85, with the figure leaning towards a bullish end. 13 analysts who tracked the company were contacted by Reuters. Amongst them, 2 rated the stock as a hold while the remaining 11 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 11 analysts rated Voyager Therapeutics, Inc. (NASDAQ:VYGR) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.

Voyager Therapeutics, Inc. (VYGR)’s current-quarter revenues are projected to climb by nearly 443.8% to hit $10.92 million, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over 1003.2% from $7.62 million to a noteworthy $84.05 million. At the other end of the current quarter income statement, Voyager Therapeutics, Inc. is expected to see its adjusted earnings surge by roughly -15.7% to hit $-0.81 per share. For the fiscal year, VYGR’s earnings are projected to climb by roughly 41.1% to hit $-1.62 per share.